Intensity Therapeutics Inc
NASDAQ:INTS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Intensity Therapeutics Inc (INTS) under the Base Case is 16.5804 USD per share. Compared with the current market price of 2.7878 USD, the stock appears Undervalued by 83% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Intensity Therapeutics Does
Intensity Therapeutics is a clinical-stage biotechnology company that develops cancer treatments designed to be injected directly into a tumor. Its approach uses the tumor itself to help trigger an immune response, with the goal of shrinking the injected tumor and helping the body attack cancer elsewhere. The company’s lead work is focused on solid tumors, where doctors and cancer centers would be the users if the therapies reach market.
- Headquarters
- United States of America US
- Employees
- 3
- IPO date
- Jun 30, 2023
Continue INTS Research
Decided on Intensity Therapeutics? Get an email when INTS reaches the price you’d buy at. Free with an account.
What is the Intrinsic Value of one INTS stock?
The intrinsic value for Intensity Therapeutics Inc (INTS) under the Base Case is 16.5804 USD.
Is INTS stock undervalued or overvalued?
Compared with the current market price of 2.7878 USD, the stock appears Undervalued by 83% .